NICE Knockback For BMS Immunotherapy Opdivo In Lung Cancer
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb Co.'s immunotherapy Opdivo (nivolumab) is not cost-effective and should not be provided for NHS patients with lung cancer in England and Wales, according to draft guidance from the health technology assessment body NICE. BMS had offered a confidential discounting scheme to reduce the cost below its list price of £5,200 per month (for a patient weighing 73kg), but this failed to sway the National Institute for Health and Care Excellence.